Mizuno, Kayoko
Takeuchi, Masato
Kanazawa, Yuji
Kishimoto, Yo
Suehiro, Atsushi
Iwanaga, Ken
Kawakami, Koji http://orcid.org/0000-0002-7477-4071
Omori, Koichi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP8ek0109375h0001)
Japan Foundation (the Japan Intractable Diseases (Nanbyo) Research Foundation: 2018C02)
Article History
Received: 16 April 2021
Accepted: 7 February 2022
First Online: 16 February 2022
Declarations
:
: Koji Kawakami has received research funds from Eisai Co. Ltd.; Kyowa Kirin Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Pfizer Inc.; Stella Pharma Corporation; CMIC Co. Ltd.; Suntory Beverage & Food Ltd.; Mitsubishi Corporation, and Real World Data Co. Ltd.; consulting fees from LEBER Inc.; JMDC Inc.; Shin Nippon Biomedical Laboratories Ltd.; Kaken Pharmaceutical Co. Ltd.; and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems; Inc.; honorarium from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, and Pharma Business Academy; and holds stock in Real World Data Co. Ltd.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The requirement for informed patient consent was waived because this study was a secondary analysis of anonymous patient data.